Long-term effects of insulin glargine on the risk of breast cancer

[1]  H. Werner,et al.  Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor , 2010, Diabetologia.

[2]  D. Balzi,et al.  Doses of Insulin and Its Analogues and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients , 2010, Diabetes Care.

[3]  D. Mayer,et al.  Treatment with insulin glargine (Lantus®) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells , 2010, Archives of physiology and biochemistry.

[4]  S. Krähenbühl,et al.  Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer , 2010, Diabetes Care.

[5]  N. Tennagels,et al.  In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites , 2010, PloS one.

[6]  S. Hernández-Díaz,et al.  Diabetes therapy and cancer risk: causal effects and other plausible explanations , 2010, Diabetologia.

[7]  L. Hemkens,et al.  Insufficient evaluation of adverse events is not a proof of safety , 2010, Diabetologia.

[8]  J. Råstam,et al.  No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis , 2009, Diabetologia.

[9]  P. Home,et al.  Combined randomised controlled trial experience of malignancies in studies using insulin glargine , 2009, Diabetologia.

[10]  L. Smeeth,et al.  Insulin glargine and malignancy: an unwarranted alarm , 2009, The Lancet.

[11]  H. Colhoun,et al.  Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group , 2009, Diabetologia.

[12]  G. Steineck,et al.  Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden , 2009, Diabetologia.

[13]  E. Gale,et al.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.

[14]  L. Hemkens,et al.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study , 2009, Diabetologia.

[15]  V. Ehemann,et al.  Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. , 2009, Endocrine-related cancer.

[16]  A. Lal,et al.  Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis , 2009, Canadian Medical Association Journal.

[17]  H. Masoudi,et al.  Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. , 2008, Cancer research.

[18]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[19]  H. Werner,et al.  Similarities and differences between insulin and IGF-I: Structures, receptors, and signalling pathways , 2008, Archives of physiology and biochemistry.

[20]  S. Suissa,et al.  Hormone replacement therapy use and variations in the risk of breast cancer , 2007, BJOG : an international journal of obstetrics and gynaecology.

[21]  A. Berghold,et al.  Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. , 2007, The Cochrane database of systematic reviews.

[22]  JoAnn E Manson,et al.  Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. , 2003, Diabetes care.

[23]  L. Schäffer,et al.  Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. , 2000, Diabetes.

[24]  R. Baserga.  The IGF-I receptor in cancer research. , 1999, Experimental cell research.

[25]  Welch Hg,et al.  Using Autopsy Series To Estimate the Disease “Reservoir” for Ductal Carcinoma in Situ of the Breast: How Much More Breast Cancer Can We Find? , 1997 .

[26]  T. Walley,et al.  The UK General Practice Research Database , 1997, The Lancet.

[27]  H. Heinzl,et al.  Assessing interactions of binary time-dependent covariates with time in cox proportional hazards regression models using cubic spline functions. , 1996, Statistics in medicine.

[28]  H. Klein,et al.  Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. , 1996, The Biochemical journal.

[29]  H. Adami,et al.  Transient increase in the risk of breast cancer after giving birth. , 1994, The New England journal of medicine.

[30]  J. Brange,et al.  Monomeric insulins obtained by protein engineering and their medical implications , 1988, Nature.

[31]  Robert H. Bell,et al.  Insulin receptor expression by human prostate cancers , 2009, The Prostate.